Adjuvant therapy in primary GIST: state-of-the-art

P Reichardt, JY Blay, I Boukovinas, T Brodowicz, JM Broto, PG Casali, M Decatris, M Eriksson, H Gelderblom, P Kosmidis, A le Cesne, AL Pousa, M Schlemmer, Jaap Verweij, H Joensuu

Research output: Contribution to journalArticleAcademicpeer-review

64 Citations (Scopus)


The management of primary gastrointestinal stromal tumours (GISTs) has evolved with the introduction of adjuvant therapy. Recently reported results of the SSG XVIII/AIO trial by the Scandinavian Sarcoma Group (SSG) and the German Working Group on Medical Oncology (AIO) represent a significant change in the evidence for adjuvant therapy duration. The objectives of this European Expert Panel meeting were to describe the optimal management and best practice for the systemic adjuvant treatment of patients with primary GISTs. A panel of medical oncology experts from European sarcoma research groups were invited to a 1-day workshop. Several questions and discussion points were selected by the organising committee prior to the conference. The experts reviewed the current literature of all clinical trials available on adjuvant therapy for primary GISTs, considered the quality evidence and formulated recommendations for each discussion point. Clinical issues were identified and provisional clinical opinions were formulated for adjuvant treatment patient selection, imatinib dose, duration and patient recall, mutational analysis and follow-up of primary GIST patients. Adjuvant imatinib 400 mg/day for 3 years duration is a standard treatment in all patients with significant risk of recurrence following resection of primary GISTs. Patient selection for adjuvant therapy should be based on any of the three commonly used patient risk strati Key points in systemic adjuvant treatment and clinical management of primary GISTs as well as open questions were identified during this European Expert Panel meeting on GIST management.
Original languageUndefined/Unknown
Pages (from-to)2776-2781
Number of pages6
JournalAnnals of Oncology
Issue number11
Publication statusPublished - 2012

Research programs

  • EMC MM-03-86-08

Cite this